Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:IONS NASDAQ:SDGR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.62$21.67$19.69▼$28.35$3.70B0.841.11 million shs3.23 million shsASNDAscendis Pharma A/S$230.83$232.32$160.86▼$250.74$14.40B0.39575,089 shs891,707 shsIONSIonis Pharmaceuticals$74.12$74.87$36.45▼$86.74$12.25B0.371.55 million shs2.98 million shsSDGRSchrodinger$15.76$13.27$10.94▼$23.75$1.16B1.641.23 million shs1.56 million shsUTHRUnited Therapeutics$536.59$564.47$272.12▼$609.35$22.78B0.57520,467 shs1.65 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+2.51%+2.46%+3.00%-4.80%ASNDAscendis Pharma A/S0.00%+5.86%-6.57%+5.86%+30.49%IONSIonis Pharmaceuticals0.00%+1.15%-1.91%+4.70%+98.13%SDGRSchrodinger0.00%+9.07%+18.50%+32.77%-22.97%UTHRUnited Therapeutics0.00%-1.72%-5.60%+2.95%+84.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.62$21.67$19.69▼$28.35$3.70B0.841.11 million shs3.23 million shsASNDAscendis Pharma A/S$230.83$232.32$160.86▼$250.74$14.40B0.39575,089 shs891,707 shsIONSIonis Pharmaceuticals$74.12$74.87$36.45▼$86.74$12.25B0.371.55 million shs2.98 million shsSDGRSchrodinger$15.76$13.27$10.94▼$23.75$1.16B1.641.23 million shs1.56 million shsUTHRUnited Therapeutics$536.59$564.47$272.12▼$609.35$22.78B0.57520,467 shs1.65 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+2.51%+2.46%+3.00%-4.80%ASNDAscendis Pharma A/S0.00%+5.86%-6.57%+5.86%+30.49%IONSIonis Pharmaceuticals0.00%+1.15%-1.91%+4.70%+98.13%SDGRSchrodinger0.00%+9.07%+18.50%+32.77%-22.97%UTHRUnited Therapeutics0.00%-1.72%-5.60%+2.95%+84.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$31.6346.28% UpsideASNDAscendis Pharma A/S 3.00Buy$295.3927.97% UpsideIONSIonis Pharmaceuticals 2.90Moderate Buy$101.8037.34% UpsideSDGRSchrodinger 2.33Hold$20.2528.49% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.4215.44% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, UTHR, SDGR, IONS, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026IONSIonis Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$114.00 ➝ $122.006/15/2026IONSIonis Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$108.006/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/27/2026IONSIonis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.005/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026IONSIonis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$115.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/18/2026IONSIonis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.00(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.46$0.89 per share24.37$7.25 per share2.98ASNDAscendis Pharma A/S$814.57M17.68N/AN/A($2.97) per share-77.72IONSIonis Pharmaceuticals$944M12.98N/AN/A$3.02 per share24.54SDGRSchrodinger$255.87M4.55N/AN/A$4.94 per share3.19UTHRUnited Therapeutics$3.18B7.16$32.98 per share16.27$164.81 per share3.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.8327.3727.1434.30%9.61%7.07%8/5/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6726.6221.43N/A57.87%N/A-8.37%8/6/2026 (Estimated)IONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%8/5/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0919.8117.261.7540.62%19.24%17.25%7/29/2026 (Estimated)Latest ACAD, UTHR, SDGR, IONS, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ASNDAscendis Pharma A/S0.791.000.72IONSIonis Pharmaceuticals2.754.104.09SDGRSchrodingerN/A2.742.74UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AIONSIonis Pharmaceuticals93.86%SDGRSchrodinger79.05%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ASNDAscendis Pharma A/S40.00%IONSIonis Pharmaceuticals1.81%SDGRSchrodinger10.10%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableIONSIonis Pharmaceuticals1,402165.26 million162.27 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableACAD, UTHR, SDGR, IONS, and ASND HeadlinesRecent News About These CompaniesUnited Therapeutics Corporation $UTHR Stake Raised by TobamJune 20 at 5:04 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of StockJune 19 at 7:06 AM | insidertrades.comWick Capital Partners LLC Takes $75.86 Million Position in United Therapeutics Corporation $UTHRJune 19 at 6:31 AM | marketbeat.comSeven Fleet Capital Management LP Acquires New Stake in United Therapeutics Corporation $UTHRJune 19 at 6:07 AM | marketbeat.comPacer Advisors Inc. Sells 97,199 Shares of United Therapeutics Corporation $UTHRJune 19 at 5:43 AM | marketbeat.comInspire Investing LLC Has $5.88 Million Stock Holdings in United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comEvolve Private Wealth LLC Takes $6.83 Million Position in United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comElmind Capital LP Buys Shares of 11,000 United Therapeutics Corporation $UTHRJune 18, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Holdings Increased by Eversept Partners LPJune 18, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockJune 17, 2026 | insidertrades.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockJune 16, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by L2 Asset Management LLCJune 16, 2026 | marketbeat.comUniversity of Texas Texas AM Investment Management Co. Makes New Investment in United Therapeutics Corporation $UTHRJune 16, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Bought by Sofinnova Investments Inc.June 16, 2026 | marketbeat.comNicholas Investment Partners LP Increases Stake in United Therapeutics Corporation $UTHRJune 14, 2026 | marketbeat.comEventide Asset Management LLC Cuts Stock Holdings in United Therapeutics Corporation $UTHRJune 14, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Position Lowered by Epoch Investment Partners Inc.June 14, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Aurora Investment CounselJune 14, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,185,385.00 in StockJune 14, 2026 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,492,900.00 in StockJune 12, 2026 | marketbeat.comMartine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) StockJune 12, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesQuantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026Everpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 2026What IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 2026Why These Three Big Buybacks Are Sending Very Different Signals to InvestorsBy Leo Miller | June 1, 2026ACAD, UTHR, SDGR, IONS, and ASND Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.62 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$21.49 -0.13 (-0.58%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$230.83 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$227.73 -3.10 (-1.34%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Ionis Pharmaceuticals NASDAQ:IONS$74.12 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$74.37 +0.25 (+0.33%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Schrodinger NASDAQ:SDGR$15.76 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$15.47 -0.29 (-1.87%) As of 06:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.United Therapeutics NASDAQ:UTHR$536.59 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$535.13 -1.46 (-0.27%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
